In brief
The U.S. Food and Drug Administration has granted approval to daraxonrasib (Rasonque), a daily pill that shows promising results in malignant pancreatic cancer. Clinical trials involving 500 patients reported an average survival of 13.2 months versus 6.6 months for chemotherapy. Side‑effect rates are lower, with 44% severe reactions compared to 57.5% for chemo. Targeting the KRAS gene mutation that drives 90% of these tumors, the drug marks a breakthrough in a disease with high mortality and few options.
Daraxonrasib (marketed as Rasonque by Revolution Medicines) is the first drug approved by the FDA specifically for pancreatic cancer that has shown significant improvement in patient survival. In a late‑stage trial involving 500 participants, daily dosing extended the average overall survival from 6.6 months with chemotherapy to 13.2 months.
The medication works by locking onto and shutting off the mutated KRAS gene, which is present in more than 90 % of pancreatic tumors. This mechanism blocks one of the primary drivers of cancer growth and spread.
Clinical side‑effect data indicate that severe reactions affected 44 % of patients taking daraxonrasib, compared with 57.5 % in the chemotherapy group. Common symptoms include rash, diarrhoea, nausea, fatigue, and vomiting.
The FDA granted Breakthrough Therapy designation to daraxonrasib in 2025 and approved it in under eight weeks, underscoring the urgent need for new treatments in a disease that often appears too late to treat effectively. Roughly 67,000 new cases are diagnosed each year in the United States, and pancreatic cancer remains the most lethal of the major cancers, with a five‑year survival rate of about 10 %.
While the drug’s approval is a hopeful development, patients and clinicians are advised to weigh its benefits against the relatively higher side‑effect burden compared to existing therapies. Ongoing studies aim to refine dosing and monitor long‑term outcomes.
